Researchers report that retatrutide—a weight-loss injection often described as a next-generation “fat jab”—produces greater fat loss than tirzepatide (marketed as Mounjaro) in a new study. The reporting says participants lost substantial weight, with figures described as reaching about a fifth of body weight, alongside improvements in blood pressure and cholesterol.
The outlets frame retatrutide as potentially outperforming Mounjaro and highlight additional metabolic benefits beyond weight reduction. Both sources focus on the same general findings—relative effectiveness for fat loss and associated health markers—while the Mail Online also adds timing-focused language about when it could be available in Britain. The coverage does not provide detailed clinical methodology or full results in the provided excerpts, and it presents the findings through a consumer-focused lens.
Overall, the articles agree that comparative research points to stronger weight and fat-loss effects for retatrutide versus Mounjaro, and both mention improvements in cardiovascular-related measurements.
